BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12953286)

  • 1. Lead-time and overdiagnosis estimation in neuroblastoma screening.
    Spix C; Michaelis J; Berthold F; Erttmann R; Sander J; Schilling FH
    Stat Med; 2003 Sep; 22(18):2877-92. PubMed ID: 12953286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroblastoma screening at one year of age.
    Schilling FH; Spix C; Berthold F; Erttmann R; Fehse N; Hero B; Klein G; Sander J; Schwarz K; Treuner J; Zorn U; Michaelis J
    N Engl J Med; 2002 Apr; 346(14):1047-53. PubMed ID: 11932471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mass screening of neuroblastoma in Sapporo City, Japan.
    Nishi M; Miyake H; Takeda T; Kikuchi Y; Hanai J; Yonemori H; Takasugi N
    Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):327-31. PubMed ID: 1456398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.
    Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M
    Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The "Lower Saxony/Northern Rhine-Westphalia" Neuroblastoma Screening Project: on the need for epidemiologic comparison].
    Berthold F; Sander J; Baillot A; Hunneman DH; Michaelis J
    Klin Padiatr; 1992; 204(4):288-92. PubMed ID: 1518267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the mass screening for neuroblastoma ineffective?
    Nishi M; Hanai J; Fujita K; Ichimiya H; Tanaka T; Hatae Y; Takeda T
    J Exp Clin Cancer Res; 2003 Dec; 22(4):673-6. PubMed ID: 15053313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D; Etzioni R; Gulati R
    Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroblastoma: epidemiology and pattern of regression. Problems in interpreting results of mass screening.
    Carlsen NL
    Am J Pediatr Hematol Oncol; 1992 May; 14(2):103-10. PubMed ID: 1530115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Occurrence of lead poisoning during follow-up of children at risk with initial screening lead blood levels below 100 microg/L].
    Tararbit K; Carré N; Garnier R;
    Rev Epidemiol Sante Publique; 2009 Aug; 57(4):249-55. PubMed ID: 19553045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which cases are found and missed by neuroblastoma screening at 1 year? Results from the 1992 to 1995 study in three Federal States of Germany.
    Berthold F; Baillot A; Hero B; Schurr P; Nerenz A; Hunneman DH; Sander J
    J Clin Oncol; 1999 Apr; 17(4):1200. PubMed ID: 10561179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of observed and expected numbers of detected cancers in the research center for cancer prevention and screening program.
    Hamashima C; Sobue T; Muramatsu Y; Saito H; Moriyama N; Kakizoe T
    Jpn J Clin Oncol; 2006 May; 36(5):301-8. PubMed ID: 16735372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: interim results.
    Schilling FH; Berthold F; Erttmann R; Michaelis J; Spix C; Sander J; Schwarz K; Treuner J
    Med Pediatr Oncol; 2000 Dec; 35(6):701-4. PubMed ID: 11107150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of neuroblastoma after a screening program.
    Barrette S; Bernstein ML; Robison LL; Samson Y; Brossard J; Weitzman S; Woods WG
    J Clin Oncol; 2007 Nov; 25(31):4929-32. PubMed ID: 17971590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of HPLC mass screening for neuroblastoma to a decrease in mortality.
    Nishi M; Takeda T; Hatae Y; Hanai J; Fujita K; Ichimiya H; Tanaka T
    J Exp Clin Cancer Res; 2002 Mar; 21(1):73-8. PubMed ID: 12071533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of 598 cases of neuroblastoma (NB) detected by screening and changes in the age distribution and incidence of NB patients after mass screening in infants in Japan. NB Screening Study Group.
    Sawada T; Shikata T; Matsumura T; Kawakatsu H; Sugimoto T
    Prog Clin Biol Res; 1994; 385():371-5. PubMed ID: 7972233
    [No Abstract]   [Full Text] [Related]  

  • 17. Empirical Bayes screening of many p-values with applications to microarray studies.
    Datta S; Datta S
    Bioinformatics; 2005 May; 21(9):1987-94. PubMed ID: 15691856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overall survival in the intervention arm of a randomized controlled screening trial for prostate cancer compared with a clinically diagnosed cohort.
    Vis AN; Roemeling S; Reedijk AM; Otto SJ; Schröder FH
    Eur Urol; 2008 Jan; 53(1):91-8. PubMed ID: 17583416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overdiagnosis, sojourn time, and sensitivity in the Copenhagen mammography screening program.
    Olsen AH; Agbaje OF; Myles JP; Lynge E; Duffy SW
    Breast J; 2006; 12(4):338-42. PubMed ID: 16848843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.